Skip to main content

Advertisement

SpringerLink
Log in

Treating high-density lipoprotein cholesterol: A return to inhibition of cholesteryl ester transfer protein?

  • Invited Commentary
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cobain MR, Pencina MJ, D’Agostino RB, et al.: Lifetime risk for developing dyslipidemia: the Framingham Off-spring Study. Am J Cardiol 2007, 7:623–630.

    Google Scholar 

  2. Campbell CY, Rivera JJ, Blumenthal RS: Residual risk in statin-treated patients: future therapeutic options. Curr Cardiol Rep 2007, 6:499–505.

    Article  Google Scholar 

  3. Cannon CP: High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone 2007, 8(Suppl 6):S14–S23.

    Article  PubMed  Google Scholar 

  4. Grundy SM: Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006, 8(Suppl 1):S21–S27.

    Article  PubMed  Google Scholar 

  5. Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310

    Article  PubMed  CAS  Google Scholar 

  6. Barter PJ, Brewer HB, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target to raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160–167.

    Article  PubMed  CAS  Google Scholar 

  7. Sandhofer A, Kaser S, Ritsch A, et al.: Cholesteryl ester transfer protein in metabolic syndrome. Obesity (Silver Spring) 2006, 14:812–818.

    Article  CAS  Google Scholar 

  8. Li TY, Zhang C, Asselbergs FW, et al.: Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men. Am J Clin Nutr 2007, 86:1524–1529.

    PubMed  CAS  Google Scholar 

  9. Porchay-Baldérelli I, Péan F, Bellili N, et al.; DIABHYCAR Study Group: The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients. Diabetes Care 2007, 30:2863–2867.

    Article  PubMed  CAS  Google Scholar 

  10. Willer CJ, Sanna S, Jackson AU, et al.: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008 [Epub ahead of print].

  11. de Vries R, Perton FG, Dallinga-Thie GM, et al.: Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005, 54:3554–3559.

    Article  PubMed  Google Scholar 

  12. Zeller M, Masson D, Farnier M, et al.: High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007, 50:1948–1955.

    Article  PubMed  CAS  Google Scholar 

  13. Barter PJ, Caulfield M, Eriksson M, for the ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

  14. Krishna R, Anderson MS, Bergman AJ, et al.: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907–1914.

    Article  PubMed  CAS  Google Scholar 

  15. Kastelein JJ, van Leuven SI, Burgess L, for the RADIANCE 1 Investigators: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630.

    Article  PubMed  CAS  Google Scholar 

  16. Bots ML, Viseren FL, Evans GW, for the RADIANCE 2 Investigators: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153–160.

    Article  PubMed  CAS  Google Scholar 

  17. Nissen SE, Tardif JC, Nicholls SJ, for the ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.

    Article  PubMed  CAS  Google Scholar 

  18. Bloomfield D, Carlson G, Sapre A, et al.: Efficacity and safety of the CETP inhibitor MK-0869 in dyslipidemic patients [abstract]. J Clin Lipidol 2007, 1:327.

    Google Scholar 

  19. O’Neil E, Sparrow CP, Chen S, et al.: Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor [abstract]. J Clin Lipidol 2007, 1:367.

    Google Scholar 

  20. Singh IM, Shishehbor MH, Ansell BJ: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786–798.

    Article  PubMed  CAS  Google Scholar 

  21. Yvan-Charvet L, Matsuura F, Wang N, et al.: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132–1138.

    Article  PubMed  CAS  Google Scholar 

  22. Brousseau ME, Diffenderfer MR, Millar JS, et al.: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057–1064.

    Article  PubMed  CAS  Google Scholar 

  23. Millar JS, Brousseau ME, Diffenderfer MR, et al.: Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006, 26:1350–1356.

    Article  PubMed  CAS  Google Scholar 

  24. Gong M, Wilson M, Kelly T, et al.: HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003, 111:1579–1587.

    PubMed  CAS  Google Scholar 

  25. Hu RM, Chuang MY, Prins B, et al.: High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells. J Clin Invest 1994, 93:1056–1062.

    Article  PubMed  CAS  Google Scholar 

  26. Martin-Nizard F, Sqalli-Houssaini H, Walters-Laporte E, et al.: Oxidized high-density lipoproteins modulate endothelin secretion by adult bovine aortic endothelial cells. J Cardiovasc Risk 1995, 2:263–267.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculté de Pharmacie, Physiologie, Université du Droit et de la Santé de Lille 2, 3 rue du Professeur Laguesse, BP83, 59006, Lille, France

    Patrick Duriez

Authors
  1. Patrick Duriez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Duriez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duriez, P. Treating high-density lipoprotein cholesterol: A return to inhibition of cholesteryl ester transfer protein?. Curr Atheroscler Rep 10, 177–179 (2008). https://doi.org/10.1007/s11883-008-0027-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0027-x

Keywords

Search

Navigation